JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers

Maithili P. Dalvi, Elisabeth D. Martinez

Research output: Contribution to journalArticle


Resistance to standard taxane-platin chemotherapy and tumor relapse are a major challenge in the treatment of non-small cell lung cancers (NSCLC). Our recent study identified JumonjiC demethylase inhibitors as a highly potent therapeutic strategy for targeting chemoresistant tumors and for preventing the emergence of drug-tolerant clones from taxane-platin treated NSCLCs.

Original languageEnglish (US)
Article numbere1345352
JournalMolecular and Cellular Oncology
Issue number5
StatePublished - Sep 3 2017



  • Drug resistance
  • JmjC demethylases
  • Jumonji inhibitors
  • KDM
  • Non-small cell lung cancer
  • Standard chemotherapy
  • Taxane-platin

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine

Cite this